PRA Health Sciences (NASDAQ:PRAH) Has Just Had Its PT Upped by Professional Analysts at Jefferies & Co to $49.50

Share

Stock Analysis:PRA Health Sciences (NASDAQ:PRAH) Target Raised

In an analyst research report issued to clients by Jefferies & Co on Tuesday morning, PRA Health Sciences (NASDAQ:PRAH) had its price target raised to $49.50. The firm now has a solid Buy rating on shares.

From a total of 7 analysts covering PRA Health Sciences (NASDAQ:PRAH) stock, 6 rate it a ”Buy”, 1 a “Sell”, and 2 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is $49.5 while the lowest target price is $37.5. The mean of all analyst targets is $45.86 with a 8.23% above today’s ($44.81) stock price. PRA Health Sciences was the topic of 6 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. SunTrust initiated shares on November 19 with “Neutral” rating. Credit Suisse reinitiated PRAH stock in a recent report from August 14 with “Outperform” rating.

The stock increased 4.99% or $2.13 on December 8, striking $44.81. Approximately shares of stock traded hands. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 54.52% since May 6, 2015 and is uptrending. It has outperformed by 55.31% the S&P500.

PRA Health Sciences, Inc. is a contract research organization . The company has a market cap of $2.57 billion. The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It has 113.93 P/E ratio. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

According to Zacks Investment Research, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.” Get a free copy of the Zacks research report on PRA Health Sciences Inc (PRAH).

COMMENTS: